Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.

Jessica L Wojtaszek | Nimrat Chatterjee | Javaria Najeeb | Azucena Ramos | Minhee Lee | Ke Bian | Jenny Y Xue | Benjamin A Fenton | Hyeri Park | Deyu Li | Michael T Hemann | Jiyong Hong | Graham C Walker | Pei Zhou
Cell | 2019

Intrinsic and acquired drug resistance and induction of secondary malignancies limit successful chemotherapy. Because mutagenic translesion synthesis (TLS) contributes to chemoresistance as well as treatment-induced mutations, targeting TLS is an attractive avenue for improving chemotherapeutics. However, development of small molecules with high specificity and in vivo efficacy for mutagenic TLS has been challenging. Here, we report the discovery of a small-molecule inhibitor, JH-RE-06, that disrupts mutagenic TLS by preventing recruitment of mutagenic POL ζ. Remarkably, JH-RE-06 targets a nearly featureless surface of REV1 that interacts with the REV7 subunit of POL ζ. Binding of JH-RE-06 induces REV1 dimerization, which blocks the REV1-REV7 interaction and POL ζ recruitment. JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice, establishing a framework for developing TLS inhibitors as a novel class of chemotherapy adjuvants.

Pubmed ID: 31178121

Associated grants

  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM007287
  • Agency: NCI NIH HHS, United States
    Id: R15 CA213042
  • Agency: NCI NIH HHS, United States
    Id: R21 CA191448
  • Agency: NCRR NIH HHS, United States
    Id: S10 RR028976
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES028865
  • Agency: NIEHS NIH HHS, United States
    Id: R35 ES028303

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


New England Biolabs (tool)

RRID:SCR_013517

An Antibody supplier

View all literature mentions

Phenix (tool)

RRID:SCR_014224

A Python-based software suite for the automated determination of molecular structures using X-ray crystallography and other methods. Phenix includes programs for assessing data quality, experimental phasing, molecular replacement, model building, structure refinement, and validation. It also includes tools for reflection data and creating maps and models. Phenix can also be used for neutron crystallography. Tutorials and examples are available in the documentation tab.

View all literature mentions

XDS Program Package (tool)

RRID:SCR_015652

Software for x-ray detection and processing single-crystal monochromatic diffraction data recorded by the rotation method. XDS can process data images from CCD-, imaging-plate-, multiwire-, and pixel-detectors in a variety of formats.

View all literature mentions